Drug Information

General Information
Drug ID
DR00161
Drug Name
SN-38
Synonyms
(+)-7-ETHYL-10-HYDROXYCAMPTOTHECIN; (S)-4,11-Diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 0H43101T0J; 10-Hydroxy-7-ethylcamptothecin; 113015-38-6; 7-Ethyl-10-hydroxy camptothecin; 7-Ethyl-10-hydroxy-20(S)-camptothecin; 7-Ethyl-10-hydroxy-camptothecin; 7-Ethyl-10-hydroxycamptothecin; 7-Ethyl-10-hydroxycamptothecine; 86639-52-3; Captothecin, 7-ethyl-10-hydroxy-; LE-SN38; NSC673596; SN 38; SN 38 lactone; SN38; UNII-0H43101T0J
Drug Type
Small molecular drug
Indication Colon cancer [ICD11: 2B90.Z] Phase 2 [1]
Structure
3D MOL 2D MOL
Formula
C22H20N2O5
Canonical SMILES
CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)O
InChI
InChI=1S/C22H20N2O5/c1-3-12-13-7-11(25)5-6-17(13)23-19-14(12)9-24-18(19)8-16-15(20(24)26)10-29-21(27)22(16,28)4-2/h5-8,25,28H,3-4,9-10H2,1-2H3/t22-/m0/s1
InChIKey
FJHBVJOVLFPMQE-QFIPXVFZSA-N
CAS Number
CAS 86639-52-3
Pharmaceutical Properties Molecular Weight 392.4 Topological Polar Surface Area 100
Heavy Atom Count 29 Rotatable Bond Count 2
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 6
XLogP
1.4
PubChem CID
104842
PubChem SID
10233636 , 103220117 , 103996165 , 104373061 , 11430409 , 12012598 , 126588659 , 126625532 , 126656661 , 126666539 , 127855413 , 13355 , 134340412 , 134340540 , 135062353 , 135693781 , 135710073 , 136377612 , 136897516 , 136911131 , 137138435 , 142309355 , 144115510 , 14805294 , 14805295 , 152059852 , 152164367 , 152200177 , 152245349 , 162178284 , 162223790 , 163367112 , 164178264 , 164194982 , 44434437 , 49835447 , 50028359 , 50112971 , 515301 , 56311337 , 56311445 , 56311571 , 56312630 , 57337873 , 622834 , 71831605 , 80486942 , 87559919 , 89360249 , 92712502
ChEBI ID
CHEBI:8988
TTD Drug ID
D0B6YB
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
MRP1 Transporter Info Multidrug resistance-associated protein 1 Substrate [3]
MRP2 Transporter Info Multidrug resistance-associated protein 2 Substrate [4]
MRP4 Transporter Info Multidrug resistance-associated protein 4 Substrate [5]
OATP1B1 Transporter Info Organic anion transporting polypeptide 1B1 Substrate [6]
OATP1B3 Transporter Info Organic anion transporting polypeptide 1B3 Substrate [7]
Drug-Transporter Activity Data
Drug-Transporter Activity Data BCRP Transporter Info Km = 4 microM Human lung carcinoma cells (PC-6/SN2-5H)-BCRP [2]
MRP2 Transporter Info Km = 180 microM Bile canalicular membrane vesicles-MRP2 [4]
References
1 Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer. Cancer. 2013 Dec 15;119(24):4223-30.
2 Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem Biophys Res Commun. 2001 Nov 9;288(4):827-32.
3 ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol. 1999 May;55(5):921-8.
4 Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters. Cancer Res. 1998 Nov 15;58(22):5137-43.
5 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
6 Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
7 Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett. 2008 Feb 18;260(1-2):163-9.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.